AbbVie raises its 2026 adjusted earnings forecast to $13.95–$13.99 per share
AbbVie reported Q3 net revenues of $17.4B, up 10.3%. Immunology and neuroscience portfolios grew 16.3% and 19.4% respectively. The company raised its 2026 adjusted EPS forecast to $13.95–$13.99 and announced a 5.2% dividend increase for 2027. AbbVie completed the acquisition of Apogee Therapeutics and received FDA approval for Skyrizi in Crohn's disease.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise reinforce AbbVie's growth narrative, supporting a bullish stance.
Market read
Strong earnings and guidance lift for a large‑cap pharma name can drive sector momentum.
What to watch
Acquisition integration risk and the unfavorable IPR&D expense could temper upside.
Background
AbbVie announced Q3 results, completed the Apogee Therapeutics acquisition, and received FDA approval for Skyrizi SC induction.
Ticker impact
AbbVie raised its 2026 adjusted earnings forecast to $13.95–$13.99 per share and reported strong Q3 results.
likely upward pressure as investors price in the higher earnings outlook
The new EPS range is materially above prior guidance and reflects strong revenue growth across multiple portfolios.
Market effects
Positive earnings outlook may lift other large‑cap pharma stocks.
U.S. healthcare sector likely to see modest gains.
Guidance raise could influence global biotech sentiment.
Counterpoint
If the guidance increase is already priced in, the stock could face a short‑term pullback.
Key entities
- companyAbbVie
U.S. pharmaceutical company reporting Q3 results and raising guidance.
- companyApogee Therapeutics
Acquired by AbbVie to expand its immunology pipeline.
